Register or Sign in to Save this opportunity, or Send an Inquiry.
Epigenetic Therapy Testing of a Family of Novel DNA Methyl Transferase Inhibitors
AmorChem Canada flag Canada
Abstract ID:
Four novel DNA methyl transferase inhibitors (DNMTIs) are being developed and tested. DNMTIs are currently used to treat patients with a form of leukemia called myelodysplastic syndrome (MDS).
Send an Inquiry

DNA methylation (and demethylation) is one of several regulators of gene transcription. Aberrant DNA methylation is an epigenetic mechanism that can inactivate the expression of certain genes involved in the suppression of tumorigenesis such as tumor suppressor genes, genes that suppress apoptosis, metastasis and angiogenesis, genes that repair DNA and genes that express tumor-associated antigens.

Four novel DNA methyl transferase inhibitors (DNMTIs) have been designed, synthesized and are being tested. Our lead nucleoside is different from the approved DNMTIs, such that it inhibits DNMT in both solid tumor and hematologic tumor cell lines and has shown activity in cell lines resistant to 5-azadC. It is more active as a DNMTI and less cytotoxic than 5-azaC.

Type of Business Relationship Sought
Out-licensing or collaboration
Last Updated Jul 2017
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833